EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.04 HKD | +33.33% |
|
+25.00% | +17.65% |
| 2023 | Extrawell Pharmaceutical Swings to Fiscal H1 Loss on Fair Value Losses | MT |
| 2023 | Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 427.8 | 255.7 | 215.1 | 372.8 | 207.9 | 160.1 |
| Enterprise Value (EV) 1 | 324.8 | 153.9 | 150.6 | 317.5 | 178.7 | 158.4 |
| P/E ratio | 16.1 x | 4.9 x | 3.2 x | -3.08 x | 1.99 x | 1.52 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 4.99 x | 2.87 x | 2.77 x | 4.73 x | 2.81 x | 2.21 x |
| EV / Revenue | 3.79 x | 1.72 x | 1.94 x | 4.03 x | 2.42 x | 2.18 x |
| EV / EBITDA | -30 x | -14.4 x | -68.9 x | -64.8 x | -27.9 x | -34.2 x |
| EV / FCF | 109 x | -8.24 x | -2.97 x | -36.6 x | -18.8 x | -10.8 x |
| FCF Yield | 0.92% | -12.1% | -33.7% | -2.73% | -5.33% | -9.28% |
| Price to Book | 0.4 x | 0.24 x | 0.19 x | 0.36 x | 0.18 x | 0.12 x |
| Nbr of stocks (in thousands) | 2,390,000 | 2,390,000 | 2,390,000 | 2,390,000 | 2,390,000 | 2,390,000 |
| Reference price 2 | 0.1790 | 0.1070 | 0.0900 | 0.1560 | 0.0870 | 0.0670 |
| Announcement Date | 18-07-19 | 19-07-19 | 20-07-27 | 21-07-27 | 22-07-28 | 23-07-28 |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 85.76 | 89.22 | 77.58 | 78.8 | 73.92 | 72.58 |
| EBITDA 1 | -10.83 | -10.68 | -2.187 | -4.903 | -6.403 | -4.632 |
| EBIT 1 | -17.22 | -16.97 | -8.081 | -10.87 | -12.94 | -11.28 |
| Operating Margin | -20.08% | -19.02% | -10.42% | -13.79% | -17.51% | -15.54% |
| Earnings before Tax (EBT) 1 | 29.19 | 63.37 | 85.49 | -119.7 | 132.3 | 130.9 |
| Net income 1 | 29.93 | 64.03 | 83.28 | -121.1 | 130.6 | 129.3 |
| Net margin | 34.9% | 71.77% | 107.34% | -153.67% | 176.65% | 178.11% |
| EPS 2 | 0.0111 | 0.0218 | 0.0281 | -0.0507 | 0.0437 | 0.0440 |
| Free Cash Flow 1 | 2.978 | -18.69 | -50.72 | -8.669 | -9.531 | -14.71 |
| FCF margin | 3.47% | -20.95% | -65.37% | -11% | -12.89% | -20.27% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | 9.95% | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 18-07-19 | 19-07-19 | 20-07-27 | 21-07-27 | 22-07-28 | 23-07-28 |
1HKD in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 103 | 102 | 64.5 | 55.4 | 29.2 | 1.68 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 2.98 | -18.7 | -50.7 | -8.67 | -9.53 | -14.7 |
| ROE (net income / shareholders' equity) | 2.8% | 5.95% | 7.78% | -11% | 11.9% | 10.6% |
| ROA (Net income/ Total Assets) | -0.9% | -0.88% | -0.41% | -0.56% | -0.65% | -0.51% |
| Assets 1 | -3,323 | -7,283 | -20,297 | 21,663 | -20,032 | -25,326 |
| Book Value Per Share 2 | 0.4500 | 0.4500 | 0.4800 | 0.4300 | 0.4900 | 0.5400 |
| Cash Flow per Share 2 | 0.0700 | 0.0600 | 0.0500 | 0.0500 | 0.0500 | 0.0400 |
| Capex 1 | 0.12 | 1.41 | 0.16 | 0.72 | 9.63 | 6.62 |
| Capex / Sales | 0.14% | 1.58% | 0.21% | 0.91% | 13.02% | 9.12% |
| Announcement Date | 18-07-19 | 19-07-19 | 20-07-27 | 21-07-27 | 22-07-28 | 23-07-28 |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +17.65% | 12.25M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 858 Stock
- Financials Extrawell Pharmaceutical Holdings Limited